Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

Reprogramming cancer cells: back to the future

Oncogene volume 32, pages 2247–2248 (2013)Cite this article

Subjects

Abstract

Reprogramming healthy somatic cells into induced pluripotent stem cells (iPSCs) with four defined factors (Oct4, Sox2, c-Myc and Klf4) has been intensively investigated. However, reprogramming diseased cells such as cancer cells has fallen much behind. In this issue of Oncogene, Zhang et al. demonstrated that reprogrammed sarcoma cells with defined factors, as well as Nanog and Lin28, lost their tumorigenicity and dedifferentiated to mesenchymal stem cells (MSC) and hematopoietic stem cell (HSC)-like cells that can be terminally differentiated into mature connective tissues and red blood cells, suggesting sarcoma cells may be reversed back to a stage of common ancestor iPSC bifurcating for HSC and MSC ontogeny. It may, therefore, provide a novel strategy for cancer treatment via ancestor pluripotency induction

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Muller LU, Daley GQ, Williams DA . Upping the ante: recent advances in direct reprogramming. Mol Ther 2009; 17: 947–953.

    Article  CAS  Google Scholar 

  2. Okita K, Ichisaka T, Yamanaka S . Generation of germline-competent induced pluripotent stem cells. Nature 2007; 448: 313–317.

    Article  CAS  Google Scholar 

  3. Takahashi K, Yamanaka S . Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663–676.

    Article  CAS  Google Scholar 

  4. Hochedlinger K, Blelloch R, Brennan C, Yamada Y, Kim M, Chin L et al. Reprogramming of a melanoma genome by nuclear transplantation. Genes Dev 2004; 18: 1875–1885.

    Article  CAS  Google Scholar 

  5. Ramos-Mejia V, Fraga MF, Menendez P . iPSCs from cancer cells: challenges and opportunities. Trends Mol Med 2012; 18: 245–247.

    Article  CAS  Google Scholar 

  6. Carette JE, Pruszak J, Varadarajan M, Blomen VA, Gokhale S, Camargo FD et al. Generation of iPSCs from cultured human malignant cells. Blood 2010; 115: 4039–4042.

    Article  CAS  Google Scholar 

  7. Utikal J, Maherali N, Kulalert W, Hochedlinger K . Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells. J Cell Sci 2009; 122: 3502–3510.

    Article  CAS  Google Scholar 

  8. Miyoshi N, Ishii H, Nagai K, Hoshino H, Mimori K, Tanaka F et al. Defined factors induce reprogramming of gastrointestinal cancer cells. Proc Natl Acad Sci USA 2010; 107: 40–45.

    Article  CAS  Google Scholar 

  9. Chang G, Miao YL, Zhang Y, Liu S, Kou Z, Ding J et al. Linking incomplete reprogramming to the improved pluripotency of murine embryonal carcinoma cell-derived pluripotent stem cells. PLoS One 2010; 5: e10320.

    Article  Google Scholar 

  10. Choi SM, Liu H, Chaudhari P, Kim Y, Cheng L, Feng J et al. Reprogramming of EBV-immortalized B-lymphocyte cell lines into induced pluripotent stem cells. Blood 2011; 118: 1801–1805.

    Article  CAS  Google Scholar 

  11. Hu K, Yu J, Suknuntha K, Tian S, Montgomery K, Choi KD et al. Efficient generation of transgene-free induced pluripotent stem cells from normal and neoplastic bone marrow and cord blood mononuclear cells. Blood 2011; 117: e109–e119.

    Article  CAS  Google Scholar 

  12. Lin SL, Chang DC, Chang-Lin S, Lin CH, Wu DT, Chen DT et al. Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state. RNA 2008; 14: 2115–2124.

    Article  CAS  Google Scholar 

  13. Houghton J, Stoicov C, Nomura S, Rogers AB, Carlson J, Li H et al. Gastric cancer originating from bone marrow-derived cells. Science 2004; 306: 1568–1571.

    Article  CAS  Google Scholar 

  14. Berns EM, Klijn JG, van Putten WL, van Staveren IL, Portengen H, Foekens JA . c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. Cancer Res 1992; 52: 1107–1113.

    CAS  PubMed  Google Scholar 

  15. Shi Y, Glynn JM, Guilbert LJ, Cotter TG, Bissonnette RP, Green DR . Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas. Science 1992; 257: 212–214.

    Article  CAS  Google Scholar 

  16. Shi YF, Sahai BM, Green DR . Cyclosporin A inhibits activation-induced cell death in T-cell hybridomas and thymocytes. Nature 1989; 339: 625–626.

    Article  CAS  Google Scholar 

  17. Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 2002; 297: 102–104.

    Article  CAS  Google Scholar 

  18. Warrell RP, H de The, Wang ZY, Degos L . Acute promyelocytic leukemia. N Engl J Med 1993; 329: 177–189.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Stem Cell Biology, Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai Jiaotong University School of Medicine, Shanghai, China

    J-Y Lang, Y Shi & Y E Chin

Authors
  1. J-Y Lang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Y Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y E Chin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y E Chin.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lang, JY., Shi, Y. & Chin, Y. Reprogramming cancer cells: back to the future. Oncogene 32, 2247–2248 (2013). https://doi.org/10.1038/onc.2012.349

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2012.349

This article is cited by

Search

Advanced search

Quick links